• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

我如何治疗发热性中性粒细胞减少症。

How I Treat Febrile Neutropenia.

作者信息

Nucci Marcio

机构信息

Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

出版信息

Mediterr J Hematol Infect Dis. 2021 Mar 1;13(1):e2021025. doi: 10.4084/MJHID.2021.025. eCollection 2021.

DOI:10.4084/MJHID.2021.025
PMID:33747406
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7938921/
Abstract

The management of febrile neutropenia is a backbone of treating patients with hematologic malignancies and has evolved over the past decades. This article reviews my approach to the evaluation and treatment of febrile neutropenic patients. Key topics discussed include antibacterial and antifungal prophylaxis, the initial workup for fever, the choice of the empiric antibiotic regimen and its modifications, and criteria for discontinuation. For each of these questions, I review the literature and present my perspective.

摘要

发热性中性粒细胞减少症的管理是治疗血液系统恶性肿瘤患者的核心内容，在过去几十年中不断发展。本文回顾了我对发热性中性粒细胞减少症患者的评估和治疗方法。讨论的关键主题包括抗菌和抗真菌预防、发热的初始检查、经验性抗生素方案的选择及其调整，以及停药标准。对于这些问题中的每一个，我都回顾了相关文献并阐述了我的观点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2e/7938921/1b5000d51523/mjhid-13-1-e2021025f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2e/7938921/1b5000d51523/mjhid-13-1-e2021025f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e2e/7938921/1b5000d51523/mjhid-13-1-e2021025f1.jpg

相似文献

1
How I Treat Febrile Neutropenia.我如何治疗发热性中性粒细胞减少症。
Mediterr J Hematol Infect Dis. 2021 Mar 1;13(1):e2021025. doi: 10.4084/MJHID.2021.025. eCollection 2021.
2
Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.恶性肿瘤成人患者发热与中性粒细胞减少的抗菌预防和门诊管理：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2013 Feb 20;31(6):794-810. doi: 10.1200/JCO.2012.45.8661. Epub 2013 Jan 14.
3
Prophylaxis and treatment of bacterial infections: do we need new strategies?细菌感染的预防与治疗：我们是否需要新策略？
Rev Clin Exp Hematol. 2005 Dec;9(2):E4.
4
Febrile neutropenia in haematological malignancies.血液系统恶性肿瘤中的发热性中性粒细胞减少症。
J Postgrad Med. 2005;51 Suppl 1:S42-8.
5
[Empirical antifungal therapy in patients with febrile neutropenia].发热性中性粒细胞减少症患者的经验性抗真菌治疗
Drugs Today (Barc). 2010 Apr;46 Suppl C:13-20.
6
Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies.血液系统恶性肿瘤中发热性中性粒细胞减少症的循证治疗方法
Hematology Am Soc Hematol Educ Program. 2013;2013:414-22. doi: 10.1182/asheducation-2013.1.414.
7
An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients.发热性中性粒细胞减少癌症患者经验性抗生素治疗临床试验的设计与实施方法。
Eur J Cancer. 1995 Nov;31A(12):2013-22. doi: 10.1016/0959-8049(95)00292-8.
8
Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.环丙沙星和阿莫西林作为儿童癌症患者发热性中性粒细胞减少症的延续治疗药物。
Med Pediatr Oncol. 2003 Feb;40(2):93-8. doi: 10.1002/mpo.10208.
9
Wait and see or rush and switch? New questions for the management of patients with febrile neutropenia receiving antifungal prophylaxis.等待观察还是匆忙换药？发热性中性粒细胞减少症患者接受抗真菌预防治疗管理的新问题。
Mycoses. 2011 Jan;54 Suppl 1:1-6. doi: 10.1111/j.1439-0507.2010.01978.x.
10
Empiric antifungal therapy in patients with febrile neutropenia.经验性抗真菌治疗发热性中性粒细胞减少症患者。
Pharmacotherapy. 2011 Apr;31(4):369-85. doi: 10.1592/phco.31.4.369.

引用本文的文献

1
Evidence-based clinical standard for the diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease.血液肿瘤患者侵袭性肺曲霉病诊断和治疗的循证临床标准
Braz J Infect Dis. 2025 Mar-Apr;29(2):104517. doi: 10.1016/j.bjid.2025.104517. Epub 2025 Feb 24.
2
Neutropenia and Felty Syndrome in the Twenty-First Century: Redefining Ancient Concepts in Rheumatoid Arthritis Patients.21世纪的中性粒细胞减少症和费尔蒂综合征：重新定义类风湿关节炎患者的古老概念
J Clin Med. 2024 Dec 17;13(24):7677. doi: 10.3390/jcm13247677.
3
An Emergent Change in Epidemiologic and Microbiological Characteristics of Bloodstream Infections in Adults With Febrile Neutropenia Resulting From Chemotherapy for Acute Leukemia and Lymphoma at Reference Centers in Chile, Ecuador, and Peru.

本文引用的文献

1
Evaluation of the negative predictive value of methicillin-resistant nasal swab screening in patients with acute myeloid leukemia.评估耐甲氧西林的鼻腔拭子筛查在急性髓系白血病患者中的阴性预测值。
Infect Control Hosp Epidemiol. 2021 Jul;42(7):853-856. doi: 10.1017/ice.2020.1299. Epub 2020 Nov 24.
2
Early discontinuation of empirical antibiotic treatment in neutropenic patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome.中性粒细胞减少的急性髓系白血病和高危骨髓增生异常综合征患者经验性抗生素治疗的早期停药。
Antimicrob Resist Infect Control. 2020 May 27;9(1):74. doi: 10.1186/s13756-020-00729-2.
3
智利、厄瓜多尔和秘鲁参考中心接受化疗的急性白血病和淋巴瘤成人发热性中性粒细胞减少症患者血流感染的流行病学和微生物学特征的紧急变化。
Open Forum Infect Dis. 2024 Feb 1;11(3):ofae052. doi: 10.1093/ofid/ofae052. eCollection 2024 Mar.
4
Blood plasma metagenomic next-generation sequencing for identifying pathogens of febrile neutropenia in acute leukemia patients.应用血液血浆宏基因组下一代测序鉴定急性白血病发热性中性粒细胞减少症患者的病原体。
Sci Rep. 2023 Nov 20;13(1):20297. doi: 10.1038/s41598-023-47685-6.
5
Evaluation of Using Empiric Glycopeptides in Accordance with the IDSA Guidelines in Hematologic Malignancy Patients with Febrile Neutropenia.按照美国感染病学会（IDSA）指南，对血液系统恶性肿瘤伴发热性中性粒细胞减少症患者经验性使用糖肽类药物的评估。
Mediterr J Hematol Infect Dis. 2022 May 1;14(1):e2022039. doi: 10.4084/MJHID.2022.039. eCollection 2022.
6
Comparison of Empiric Antibiotic Escalation Therapy with Vancomycin (VAN) versus Linezolid (LIN) in Patients with Febrile Neutropenia.发热性中性粒细胞减少症患者经验性抗生素升级治疗中万古霉素（VAN）与利奈唑胺（LIN）的比较
Mediterr J Hematol Infect Dis. 2022 May 1;14(1):e2022032. doi: 10.4084/MJHID.2022.032. eCollection 2022.
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
伊维菌素和依维莫司治疗复发性或难治性 IDH 突变型 AML 患者的分化综合征：美国食品和药物管理局系统分析。
Clin Cancer Res. 2020 Aug 15;26(16):4280-4288. doi: 10.1158/1078-0432.CCR-20-0834. Epub 2020 May 11.
4
Baseline Chest Computed Tomography as Standard of Care in High-Risk Hematology Patients.基线胸部计算机断层扫描作为高危血液学患者的标准治疗手段
J Fungi (Basel). 2020 Mar 13;6(1):36. doi: 10.3390/jof6010036.
5
Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial.卡泊芬净与氟康唑预防方案对急性髓系白血病儿童和青年患者侵袭性真菌感染的效果：一项随机临床试验。
JAMA. 2019 Nov 5;322(17):1673-1681. doi: 10.1001/jama.2019.15702.
6
The Use of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) for the Identification of Pathogens Causing Sepsis.基质辅助激光解吸/电离飞行时间质谱（MALDI-TOF MS）在鉴定引起脓毒症病原体中的应用
J Appl Lab Med. 2019 Jan;3(4):675-685. doi: 10.1373/jalm.2018.027318. Epub 2018 Sep 13.
7
New drugs approved for acute myeloid leukaemia in 2018.2018 年批准用于急性髓系白血病的新药。
Br J Clin Pharmacol. 2019 Dec;85(12):2689-2693. doi: 10.1111/bcp.14105. Epub 2019 Dec 13.
8
Shock and Early Death in Hematologic Patients with Febrile Neutropenia.发热性中性粒细胞减少症血液学患者的休克和早期死亡。
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01250-19. Print 2019 Nov.
9
The implementation of rapid microbial identification via MALDI-ToF reduces mortality in gram-negative but not gram-positive bacteremia.通过 MALDI-ToF 进行快速微生物鉴定的实施降低了革兰氏阴性菌但没有降低革兰氏阳性菌菌血症的死亡率。
Eur J Clin Microbiol Infect Dis. 2019 Nov;38(11):2053-2059. doi: 10.1007/s10096-019-03640-w. Epub 2019 Jul 30.
10
Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients With Bacteremia in the Era of Multidrug Resistance.多重耐药时代高危中性粒细胞减少血症合并菌血症患者的不适当经验性抗生素治疗。
Clin Infect Dis. 2020 Mar 3;70(6):1068-1074. doi: 10.1093/cid/ciz319.